Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients8

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients6

Views

Views
November 20231
December 20231
January 20241
February 20240
March 20240
April 20241
May 20242
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
Spain1
 

Top cities views

Views
Chicago2
Boardman2
Burgos1